SML2876
DLCI-1
≥98% (HPLC)
别名:
5-(4-Ethyl-3-pyridinyl)-2-thiophenemethanamine, 5-(4-ethylpyridin-3-yl)thiophe-2-yl)methanamine
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Quality Level
assay
≥98% (HPLC)
form
oil
color
colorless to yellow
storage temp.
2-8°C
SMILES string
[s]1c(ccc1c2cnccc2CC)CN
InChI key
PMFPLVYHUVJODG-UHFFFAOYSA-N
Biochem/physiol Actions
DLCI-1 is an orally available potent and selective inhibitor of cytochrome P450 2A6 (CYP2A6) that significantly decreases nicotine self-administration in both male and female mice.
orally available potent and selective inhibitor of CYP2A6 that significantly decreases nicotine self-administration mice
存储类别
11 - Combustible Solids
wgk
WGK 3
Yen-Chu Chen et al.
The Journal of pharmacology and experimental therapeutics, 372(1), 21-29 (2019-10-20)
During tobacco and e-cigarette use, nicotine is mainly metabolized in the human liver by cytochrome P450 2A6 (CYP2A6). Given that a slower CYP2A6 metabolism has been associated with less vulnerability to develop nicotine dependence, the current studies sought to validate
Travis T Denton et al.
Journal of medicinal chemistry, 61(16), 7065-7086 (2018-07-12)
Cigarette smoking causes nearly one in every five deaths in the United States. The development of a specific inhibitor of cytochrome P450 2A6 (CYP2A6), the major nicotine-metabolizing enzyme in humans, which could be prescribed for the cessation of cigarette smoking
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML2876-5MG | 04061842556632 |
| SML2876-25MG | 04061842556625 |